Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.
Alnylam presented 18-month data from the HELIOS-A study of vutrisiran in hATTR amyloidosis with polyneuropathy • Source: Shutterstock

Alnylam Pharmaceuticals Inc. anticipates its drug vutrisiran will take a bigger chunk of the market for hereditary transthyretin-mediated (hATTR) amyloidosis after presenting long-term data in patients with polyneuropathy. The new 18-month data should also fulfill the requirements for the company to file for European Medicines Agency approval, whereas the drug is already under US Food and Drug Administration review based on 9-month data.

On 21 January, Alnylam presented 18-month data from the Phase III HELIOS-A study of vutrisiran at the Société Francophone du...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.